Verapamil for the Treatment of Acute Mania: A Double-Blind, Placebo-Controlled Trial

Patients admitted to our research unit at the University of Illinois at Chicago met the DSM-III-R criteria for an acute manic or mixed episode and had no significant medical conditions. All patients gave written informed consent and underwent a mean total medication washout period of 12.1 days (SD=10.6) (in-hospital washout mean=8.5 days, SD=5.9; prehospital mean=3.7 days, SD=9.0). Diagnosis was determined by a consensus of trained raters and the clinical team. The Mania Rating Scale (9), the Hamilton Depression Rating Scale (10), and the Brief Psychiatric Rating Scale (BPRS) (11) were administered at baseline and on days 3, 5, 10, 14, 17, and 21 of the trial. Intraclass correlation coefficients, based on six raters' independent ratings of five videotaped interviews, were 0.66, 0.98, and 0.91 for the three instruments, respectively.

The patients were randomly assigned to receive placebo or verapamil (80 mg) capsules three times a day, starting with two capsules on day 1, then increasing by one capsule until day 7; thereafter, they continued at the optimal dose. Vital signs were checked before each administration. Chloral hydrate (up to 4 g/day) or lorazepam (up to 2 mg/day) was used as a rescue medication during the washout period, but the dose was tapered to zero by day 10. Patients, raters, and investigators were blind to the treatment assignments.

We used an analysis of covariance (ANCOVA) to compute absolute change scores on the Mania Rating Scale, the Hamilton depression scale, and the BPRS at endpoint (last observation carried forward), with baseline scores as the covariates. We also analyzed data for patients who had a day 10 rating (end of rescue medications) and those who had at least a day 5 rating, to detect early changes. Chi-square and unpaired t tests (two-tailed) clarified differences in sex, age, and race.

Thirty-two acutely ill patients (13 female and 19 male; mean age=36.2 years, SD=10.6) entered the double-blind phase of the study. Thirty patients were in a manic episode, and one in each treatment group was in a mixed episode. The mean total and in-hospital washout days did not differ significantly between the 15 patients who received placebo and the 17 who received verapamil (t=1.5, df=30, and t=1.3, df=30, respectively). All patients given verapamil for at least 7 days tolerated the maximum dose (480 mg/day).

Ten of the 15 placebo patients and 13 of the 17 verapamil patients demonstrated psychosis at baseline, and their mean Mania Rating Scale, Hamilton depression scale, and BPRS scores did not differ. No differences were discerned at endpoint (last observation carried forward) in the comparison of covariate-adjusted mean absolute change scores (table 1). Results of ANCOVAs calculated for days 10 and 5 were also nonsignificant (for day 10, Mania Rating Scale: F=0.0, df=1,14; Hamilton depression scale: F=0.0, df=1,13; BPRS: F=0.3, df=1,13; for day 5, Mania Rating Scale: F=0.4, df=1,22; Hamilton depression scale: F=0.9, df=1,21; BPRS: F=1.0, df=1,22).

Outcomes were remarkably similar for the two groups; three placebo and four verapamil patients showed 20% improvement from their baseline Mania Rating Scale scores. At a criterion of 40% improvement, only two placebo patients and three verapamil patients responded to treatment. The two groups did not differ significantly in age (t=0.05, df=30), sex (χ²=0.00, df=1), race (χ²=0.38, df=1), presence of psychosis (χ²=0.38, df=1), total days of washout (t=1.5, df=30), total days in treatment (t=1.5, df=30), or amount of rescue medication (t=1.8, df=25).

The mean number of treatment days completed was 13.3 (SD=7.0) for the placebo group and 9.3 (SD=7.2) for the verapamil group (t=1.6, df=30, n.s.). Twenty patients continued for at least 8 days (eight in the verapamil group and 12 in the placebo group), and nine completed all 3 weeks (three in the verapamil group and six in the placebo group). Reasons for dropping out were clinical deterioration (10 verapamil subjects and eight placebo subjects) or lack of cooperation (four verapamil subjects). It is interesting that five patients taking verapamil (but none taking placebo) had to drop out during the first week.

To our knowledge, this is the only prospective parallel-design, double-blind, placebo-controlled trial of verapamil for acute mania. The study group size is second only to that in the study by Walton et al. (8). The treatment groups were similar in age, sex, baseline level of psychopathology, presence or absence of psychosis, amount and timing of rescue medication, total days of washout, and total treatment days. Twenty-three patients demonstrated psychosis, and mean baseline Mania Rating Scale scores were in the mid- to upper-20s, indicating moderate severity. We found no differences in efficacy between verapamil and placebo. Dropouts were a substantial issue because of the difficulties in managing bipolar patients receiving placebo or ineffective treatment.

Our negative results agree with those in two recent trials comparing verapamil and lithium (7, 8). Possible reasons for disparate findings from earlier reports include small sample sizes, differences in baseline symptom severity, inadequate doses, use of rescue medications, and short duration of treatment. Issues that have not been addressed include verapamil's efficacy for less severe mania, for maintenance/prophylaxis, and as an adjunct medication and the effectiveness of other calcium antagonists (e.g., nimodipine).

Although recent reviews suggest the possible benefit of calcium antagonists when standard treatments fail or cannot be tolerated (12, 13), three better-controlled studies (including ours) do not support verapamil's efficacy for acute mania. Thus, we believe it is premature to recommend this agent.

Received Aug. 27, 1997; revision received Jan. 26, 1998; accepted Feb. 26, 1998. From the Psychiatric Institute, University of Illinois at Chicago. Address reprint requests to Dr. Janicak, Psychiatric Institute, 1601 West Taylor St., Chicago, IL 60612. The authors thank Edward Altman, Psy.D., James Peterson, B.S., Sheila Dowd, M.S., and Morris Goldman, M.D., for their contributions to this work.